⌘K
Loading ticker…
Perspective Therapeutics, Inc. · Healthcare · Pharmaceutical Products
7 is not yet a leadership-grade RS read, Market Stance is 50
As of 2026-06-11, Perspective Therapeutics, Inc. (CATX) has a 3-month relative strength percentile of 7 within the TickerStance CS+ADRC universe (~5,000 tickers). The current market Stance is 50 (Neutral). Sector: Healthcare. Average daily range 6.7%, relative volume 0.82×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
CATX is held by 4 ETFs as of Mar 2026. Top owner: VTI at 0.00% weight, $14M notional. Top 3 carry $27M.
Top 4 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.00% | $14M |
| XBIState Street SPDR S&P Biotech ETF | 0.10% | $7M |
| IWMiShares Russell 2000 ETF | 0.01% | $6M |
| VXFVanguard Extended Market ETF | 0.00% | $4M |